For the quarter ending 2025-09-30, CAI has $984,571K in assets. $506,207K in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | 754,739 | 720,444 | ||
| Short-term marketable securities | 2,272 | 2,249 | ||
| Accounts receivable | 26,697 | 50,889 | ||
| Supplies | 49,303 | 40,613 | ||
| Prepaid expenses and other current assets | 21,234 | 19,124 | ||
| Total current assets | 854,245 | 833,319 | ||
| Property and equipment, net | 63,997 | 61,315 | ||
| Goodwill | 19,344 | 19,344 | ||
| Other assets | 46,985 | 41,080 | ||
| Total assets | 984,571 | 955,058 | ||
| Accounts payable | 28,999 | 28,728 | ||
| Accrued expenses and other current liabilities | 56,867 | 61,357 | ||
| Current portion of indebtedness | 164 | 95 | ||
| Total current liabilities | 86,030 | 90,180 | ||
| Long-term indebtedness, net of debt discounts | 376,296 | 373,611 | ||
| Warrant liabilities | 0 | 0 | ||
| Other long-term liabilities | 43,881 | 38,363 | ||
| Total liabilities | 506,207 | 502,154 | ||
| Redeemable convertible preferred stock-Series APreferred Stock | 0 | 0 | ||
| Redeemable convertible preferred stock-Series BPreferred Stock | 0 | 0 | ||
| Redeemable convertible preferred stock-Series CPreferred Stock | 0 | 0 | ||
| Redeemable convertible preferred stock-Series DPreferred Stock | 0 | 0 | ||
| Redeemable convertible preferred stock | 0 | 0 | ||
| Common stock 0.001 par value 2,800,000,000 and 1,150,000,000 shares authorized as of september30, 2025 and december31, 2024, respectively 283,723,897 and 36,686,819 shares issued as of september30, 2025 and december31, 2024, respectively 282,103,259 and 36,504,319 shares outstanding as of september30, 2025 and december31, 2024, respectively shares issued and outstanding include 23,446 and 662,000 unvested shares subject to repurchase as of september30, 2025 and december31, 2024, respectively | 283 | 282 | ||
| Treasury stock at cost, 1,620,638 and 182,500 shares of common stock as of september30, 2025 and december31, 2024, respectively | 16,917 | 16,917 | ||
| Additional paid-in capital | 3,124,943 | 3,123,888 | ||
| Related party promissory note receivable (see note 7) | 0 | 0 | ||
| Accumulated deficit | -2,630,693 | -2,655,018 | ||
| Accumulated other comprehensive income | 748 | 669 | ||
| Total shareholders' equity (deficit) | 478,364 | 452,904 | ||
| Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit) | 984,571 | 955,058 | ||
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)